Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.49 |
| ▸ | MAOB | P27338 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13891905 | 0.86 | ACHE (0.57) | KDM4EALDH1A1GAALMNAACHE | |
| SCHEMBL14169163 | 0.86 | ACHE (0.57) | KDM4EALDH1A1GAALMNAACHE | |
| SCHEMBL6787435 | 0.83 | KDM4E (0.49) | KDM4EALDH1A1GAALMNAACHE | |
| SCHEMBL30375827 | 0.81 | GAA (0.52) | KDM4EALDH1A1GAALMNAACHE | |
| SCHEMBL22319275 | 0.81 | GAA (0.52) | KDM4EALDH1A1GAALMNAACHE | |
| SCHEMBL22319274 | 0.81 | GAA (0.52) | KDM4EALDH1A1GAALMNAACHE | |
| SCHEMBL1893563 | 0.81 | GAA (0.52) | KDM4EALDH1A1GAALMNAACHE | |
| SCHEMBL10163625 | 0.80 | LMNA (0.51) | KDM4EALDH1A1GAALMNAACHE | |
| SCHEMBL10132576 | 0.79 | GAA (0.53) | KDM4EALDH1A1GAALMNACYP19A1 | |
| SCHEMBL10069796 | 0.79 | MAP2K3 (0.59) | KDM4EALDH1A1GAALMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922832-B1 | GLUTAMINASE INHIBITORS AND METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-1272471-B1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | ORGANON NV (NL) | 2007-10-03 | — | — | EP | disclosed |
| US-6686371-B2 | HAVING AN 11H-BENZO(B)FLUORENE, AN 11H-INDENO-(1,2-B) QUINOLINE, A BENZ(A)ANTHRACENE OR ANALOGOUS SKELETON AND AN AFFINITY FOR THE ESTROGEN RECEPTOR; CONTRACEPTIVES; MENOPAUSAL COMPLAINTS, OSTEOPOROSIS; ANTITUMOR AGENTS | AKZO NOBEL N.V. (NL) | 2004-02-03 | — | — | US | disclosed |
| EP-1339662-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| US-20030144313-A1 | Non-steroidal, tetracylic compounds for estrogen-related treatments | N.V. ORGANON (NL) | 2003-07-31 | — | — | US | disclosed |
| EP-1272471-A1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | Akzo Nobel N.V. (NL) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002046134-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2002-06-13 | — | — | WO | disclosed |
| WO-2001072713-A1 | NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS | AKZO NOBEL N.V. (NL) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144313-A1 | Non-steroidal, tetracylic compounds for estrogen-related treatments | ESRRA, ESRRB, ESRRG | KDM4E 471/4885ALDH1A1 1931/4885GAA 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.